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Acute upper gastrointestinal lesions have a multifactorial etiology but, regardless of the cause, 
they are related to mucosal barrier destruction. Since Helicobacter pylori induces a superficial 
chronic gastritis with the infiltration of neutrophils in the mucosa, it was speculated that Helicobacter 
pylori infection could also cause bleeding lesions. The diagnosis, the proper treatment and the 
revaluation of its effectiveness actually represent the prophylaxis of some diseases such as peptic 
ulcer, gastric lymphoma or mucosa-associated lymphoid tissue (MALT) and gastric cancer. These 
diseases and their severe complications are life-threatening for the patient. Periodic renewal of the 
treatment and knowing the real causes of Helicobacter pylori resistance to various antibiotics must 
always be understood by the clinician. Although Helicobacter pylori treatment fails in about 20% of 
cases, moral support of the patient by the clinician, information about possible evolutional 
complications of Helicobacter pylori infection, and periodic evaluation of the patient during therapy, 
are important tools on which the therapeutic success depends.   
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Helicobacter pylori bacterium (H. pylory) is 
the first officially recognized carcinogen. Over half 
the world's population is colonized with this 
bacterium, being the best known gram negative 
bacteria. Because histopathological changes 
induced gastric mucosam, the Helicobacter pylori 
infection  represents a determining factor in the 
occurrence of the gastrointestinal disease that can 
range from chronic gastritis without clinical 
symptoms to serious neoplastic diseases. In many 
cases, the clinical signs of upper gastrointestinal 
bleeding is the first symptom of gastrointestinal 
infection with Helicobacter pylori.The disease is the 
result of complex interactions between host and 
bacteria (1).  
History  
Barry Marshall and Robin Warren were first 
to describe the isolation and culture of a bacterium 
in the human stomach, later known as H. pylori (2). 
Their experiments on themselves using self-
ingestion (3, 4) and those on volunteers  showed 
that bacteria can colonize the human stomach and 
can induce inflammation of the stomach mucosa 
(5).  
Later research has shown that  colonization of 
H. pylori can cause chronic gastritis, peptic ulcers, 
as well as gastric lymphoma mucosa associated 
lymphoid tissue (MALT) or gastric cancer. 
Morphology 
H. pylori is a gram negative bacterium, 
measuring 2 to 4 pm in length and 0.5 to 1 pm in 
width. The body has 2 to 6 flagella and the motility 
of the flagella confers and allows rapid movement 
in viscous solutions, such as the mucus layer of the 
gastric epithelial cell (6). Unlike many other 
gastrointestinal tract pathogens, Helicobacter pylori 
does not have fimbriae adhesins. The growth occurs 
at a temperature of 34 - 40° C, with an optimum of 
37º C. Although its natural habitat is the acid gastric 
mucosa, H. pylori is considered to be a neutrophil. 
The bacterium survives to pH < 4 exposure, but the 
growth occurs only in relatively narrow pH range of 
5.5 to 8.0, with optimal growth at neutral pH (7, 8). 
Geographical distribution 
A high diversity in prevalence of H. pylori 
infection among adults in Europe was registered in 
2000, with a global prevalence in adulthood of 
18.3-82.5%, with variations from country to 
country. The highest prevalence, 82.5% for adults 
older than 18 years old, was measured in Turkey, 
on a nationally representative population; and the 
lowest prevalence, 18,3%, was found in Denmark 
(9). H. pylori prevalence shows large geographical 
variations. In various developing countries, more 
than 80% of the population is H. pylori positive, 
even at young ages. H. pylori prevalence in 
industrialized countries remains generally below 
40% and is significantly lower in children than in 
 Helicobacter pylori: diagnosis and therapy 
152 
 
adults and the elderly. In geographical areas, the 
prevalence of H. pylori correlates inversely with 
socioeconomic status, particularly regarding living 
conditions during childhood (10). 
H. pylori colonization is not a disease itself, 
but it influences the relative risk of developing 
different clinical conditions of the gastrointestinal 
tract and possibly the hepatobiliary tract. Therefore, 
routine or random testing for H. pylori  has no 
benefit, but testing should be performed in order to 
find the cause of diseases such as peptic ulcer, or, 
for the prevention of diseases, such as in subjects 
with family history of gastric cancer. In these cases, 
a positive test result justifies a treatment and a 
negative result may indicate the need to search for 
other etiological factors and preventive measures. 
For these reasons, a correct understanding of 
disorders associated with H. piloryis needed. 
Types of diseases 
Gastritis lesions occur in all  H. pylori 
infected subjects, but only a minority develop 
clinical signs of this colonization. It is estimated 
that H. pylori positive patients have a risk of 10-
20% of developing peptic ulcer and  1-2% of them  
have a risk of developing gastric cancer (11, 12, 
13). The emergence of these disorders depends on 
the type and severity of gastritis. 
In acute and chronic gastritis, due to H. pylori 
infection, the infiltration of gastric mucosa most 
frequently appears in the antrum and gastric body 
with mononuclear and neutrophil cells. Active 
chronic gastritis is the main condition linked to the 
colonization with H. pylori, and other disorders 
associated with H. pylori results in particular 
because of the chronic inflammatory process (1).  
Causes of gastritis, other than H. pylori 
infection are: excessive consumption of alcohol and 
nonsteroidal antiinflammatory drugs (NSAIDs), 
cytomegalovirus infections, and chronic idiopathic 
diseases (Crohn's disease and pernicious anemia). 
Gastric and duodenal ulcers (commonly 
referred to as peptic ulcers) are defined as mucosal 
defects with a diameter of at least 0.5 cm 
penetrating the mucous and/or muscular tunica. 
Gastric ulcers occur mainly along the lesser 
curvature of the stomach, particularly in the mucosa 
in the lining of the boundary between the body and 
antrum (1), the duodenum being the most exposed 
area to gastric acid.  
The initial worldwide reports, in the first 
decade after discovering H. pylori, associated this 
infection with about 95% of duodenal ulcers and 
85% of gastric ulcers (14). H.pylori eradication has 
changed the natural history of ulcer disease and 
ulcer recurrence was prevented almost completely 
(15). These data show that gastric and duodenal 
ulcers seem to be strongly  linked by H. pylori 
infection. However, recurrent ulcers can be 
registered after H. pylori eradication therapy 
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because of the persistence or reinfection with H. 
pylori, NSAID use, or in case of idiopathic ulcer. 
The most common complication of ulcer is 
bleeding and perforation, followed by stomach 
obstruction. It is estimated that 15-20% of peptic 
ulcers are complicated by hemorrhage and that 
approximately 40% of patients who develop  upper 
gastrointestinal bleeding are also suffering of  ulcer 
(1). 
The primary treatment for bleeding in 
ulcerous disease is endoscopic therapy, which is 
mandatory in order to establish the bleeding cause, 
to estimate its gravity, and to reduce the risk of 
recurrent bleeding. H. pylori eradication markedly 
reduces the risk of ulcer as wekk as the risk of re-
bleeding for those patients whose bleeding was 
caused by H. pylori infection (16). In general, a 
small percentage of  bleeding ulcers requires very 
careful management, and the indications for 
emergency surgery in such cases are: hemodynamic 
instability, failure in performing endoscopic 
hemostasis, and bleeding recurrences despite 
endoscopic attempts to stop it. Regarding the third 
indication, many doctors indicate surgery after two 
failed endoscopic attempts to stop the bleeding (17). 
Several studies have shown that some perforated 
peptic ulcers can be treated conservatively, but in 
any patient with a perforated peptic ulcer, showing 
peritoneal signs, surgery is required, and then it is 
necessary to decrease the acid secretion and 
antibacterial therapy in H. pylori-positive patients. 
Chronic ulcer, especially in the pyloric and bulbar 
regions, can lead to hypertrophic scars and stenosis, 
impairing the gastric eviction process. In these 
patients, malignancy as a cause of obstruction must 
first be ruled out. Most benign obstructions 
associated with H. pylori respond well to the 
eradication therapy, due to the reduction or 
disappearance of inflammation and edema. In 
refractory patients, local reconstruction surgery, or 
a distal gastric resection is mandatory (1). 
Atrophic gastritis, intestinal metaplasia and 
gastric inflammation, cancer. 
In histopathogic terms, in chronic gastritis 
induced by H. Pylori, studies have shown a loss of 
the normal architecture through the destruction of 
the gastric mucosa and gastric glands, with normal 
mucosa replaced by areas of fibrosis and intestinal 
epithelium. These changes occur in  areas of the 
gastric or duoudenal mucosa, with that  
inflammation being more severe  in 50% of subjects 
aproximativ H. pylori positive (18). The risk of 
atrophic gastritis depends on the distribution and 
the chronic active inflammation model; therefore, 
subjects with decreasing acid production show a 
faster progression to atrophic gastritis (19). 
Various studies have shown that H. pylori 
positive subjects have increased risk of developing 
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gastric cancer compared to uninfected persons by 
sequence of atrophy and metaplasia (20). This idea  
is supported by studies showing links between 
geographic prevalenceof H. pylori and incidence of 
stomach cancer (21). Factors that influence the 
occurrence of gastric atrophy and later, of stomach 
cancer in  H. pylori positive subjects are both linked 
to host and bacteria, by the severity of chronic 
inflammatory response caused by them. Therefore, 
the risk of developing gastric atrophy is increased in 
subjects with strains CagA positive (22), but also in 
those with a genetic predisposition to high yields of 
IL-1, as a result of the  response to the colonization 
of the bacteria (23). 
Although lymphoid tissue is not normally 
present in the gastric mucosa, MALT almost always 
occurs in response to infection with H. pylori. This 
tissue may give birth to a population of B 
monoclonal cells from which can proliferate and 
form a MALT lymphoma. Almost all patients with 
a MALT lymphoma are H. pylori-positive (24) and 
H. pylori positive subjects have a significantly 
increased risk of developing gastric MALT 
lymphoma (25). Different series of "case-reports" 
have shown that H. pylori eradication may lead to 
complete remission in patients with MALT 
lymphoma stage IE confined to the stomach (26, 
27). Generally, about 60 to 80% of these patients 
achieve complete remission after H. pylori 
eradication, about 10% continue to have signs of 
residual disease, while the rest show no response 
(1). 
There have been cases where the disease 
evolution depends on the correct guided therapy for 
H.pilory. For example, two subjects from the same 
family colonized with H. pyloriwho manifested 
clinical signs of disease and had positive laboratory 
tests (the mucosal lesions are highlighted by upper 
gastrointestinal endoscopy). One of them received 
the correct treatment to eradicate H. Pylori and had 
symptoms remission, while the other, who did not 
receive treatment, developed a hemorrhagic MALT 
lymphoma 10 years after the diagnosis. 
Diagnose: specificity and sensitivity. Invasive 
and/ or non-invasive tests. 
Various tests have been developed for H. 
Pylori detection, each with advantages and 
disadvantages. The available tests are generally 
divided into invasive tests, based on gastric 
specimens for histology, culture, or other 
techniques and  non-invasive tests, based on 
peripheric evidence, such as blood samples, 
respiratory tests, feces, urine or saliva for antibodies 
or bacterial antigens detection. 
Invasive methods: 
1. The histological methods are the "gold 
standard" for diagnosing H. pylori infection, 
providing information not only about the 
inflammation, but also the degree of atrophy 
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induced by the bacteria. The need for an 
experienced pathologist and the invasive method 
represent a disadvantage. It has a higher sensitivity 
and specificity of about 95%. 
2. Helicobacter pylori cultures are the 
alternative to the "gold standard"; with similar 
specificity and sensitivity, they also allow testing 
for antimicrobial susceptibility. 
3. The rapid urease test is used for the 
qualitative detection of Helicobacter pylori in the 
urease from the biopsy sample obtained after 
gastroscopy. With a specificity and sensitivity of 
more than 90% and with good cost-effectivness, the 
urease test is a quick method of diagnosis (3 
minutes), being the most common invasive method. 
It requires an additional test to confirm H. pylori 
infection. 
Non-invasive methods. 
1. Testing the urea in the exhaled air is an 
alternative to the "gold standard" with a similar 
specificity and sensitivity, the most accurate non-
invasive method of diagnosis. It is also a reliable 
test to evaluate the success of H. pylori eradication 
therapy. The major disadvantage is the high cost of 
the equipment. 
2. Antigen testing in stool samples, with a 
sensitivity greater than 90%, gas not been used 
widely, but it can be reliable for assessing the 
success of H. pylori eradication treatment.  
3. Serology (with a sensitivity of 80-90%), is 
mainly used for epidemiological studies; it cannot 
verify the evolving infection due to immunologic 
memory. 
Invasive methods cause discomfort in patients 
during diagnosis, the reason many patients refuse 
upper gastrointestinal endoscopy, especially during 
the check-up performed 4 weeks after treatment. 
Non-invasive methods of diagnosis are 
recommended as an alternative for patients under 
45 years of age who do not show symptoms such 
as: unexplained weight loss, digestive bleeding or 
repeated vomiting. Patients experiencing these 
symptoms require upper gastrointestinal endoscopy. 
When patients present acute gastroesophageal 
bleeding or are under treatment with proton pump 
inhibitors, histamine antagonists or antibiotics, most 
diagnostic tests for H. pylori infection may show 
false negative results. Because of this, it is 
mandatory that the treatment with inhibitors of 
proton pump or histamine antagonists should be 
stopped two weeks before the diagnosis test, and if 
the patients are receiving antibiotic treatment, it 
should be discontinued at least four weeks before 
testing (28). 
Blood presence in the gastric lumen can lead 
to false results due to the buffering effect it has on 
the gastric pH. If there is upper gastrointestinal 
bleeding or extended mucosal atrophy, serological 
tests can be useful, as they indicate a history of 
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exposure to H. pylori, although they do not confirm 
the presence of infection; so, it is necessary to 
repeat a non-invasive diagnostic test (if the initial 
test result was negative) 4-8 weeks after the 
hemorrhagic event (28). 
Treatment 
Helicobacter pylori eradication methods have 
continued to evolve over the last 20 years. 
Originally, the treatment used H-2 histamine 
receptor antagonists and an antibiotic with a success 
rate of 73-84% (29). In time, this therapy has been 
used less frequently, thanks to new treatment 
regimens having much better results. Currently, 
triple therapy based on proton pump inhibitors is 
the most commonly used method. This system 
includes the use of PPIs in combination with 
amoxicillin and clarithromycin. 
Eradication therapy 
1.The PPI-based triple therapy consists of 
Esomeprazole 20 mg twice a day, or 20 mg of 
omeprazole twice a day, Amoxicillin 1 g twice a 
day and Clarithromycin 500 mg twice a day. The 
treatment must be taken for 7 days; this therapy is 
highly recommended in Australian guidelines (30). 
2.The quadruple therapy includes Omeprazole 
20mg per day subsalicylate 120 mg four times a 
day, metronidazole 400 mg three times a day, 
tetracycline 500 mg four times. The treatment is 
prescribed between 7 and 14 days (30). 
Therapy control  
Because treatment of H. pylori fails for 
approximately 20% of cases for any number of 
different reasons, verifying eradication of infection 
after treatment is required in patients at risk. The 
same control is mandatory in patients with peptic 
ulcers, with MALT, and if patients whose dyspeptic 
symptoms are persistent. For efficacy evaluation of 
the treatment, 13 C marked urea or feces antigen 
tests are reccomended. Testing of urea in the 
patient's exhaled air has a precision higher than the 
antigen in feces and is preferred in these cases (28). 
Causes of treatment failure 
1. Antibiotic resistance of Helicobacter pylori 
strains.  
Diabetes can be a risk factor for resistance to 
antibiotics used for Helicobacter pylori eradication. 
Although in a study in Taiwan, a better rate of H. 
pylori eradication in patients with diabetes was 
observed (31), several studies have shown opposite 
results. Impaired microvascular gastric absorption 
lowering drugs, gastroparesis and the use of 
antibiotics for recurrent urogenital infections, 
respiratory infections, and skin resistance represent 
the main causes of H. pylori resistance to standard 
treatment in patients with diabetes. Diabetic 
gastroparesis affects approximately 40% of patients 
with diabetes type 1 and 30% of patients with 
diabetes type 2, especially those with long-term 
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illness. In a study published by Ojetti et al. (32), H. 
pylori eradication rate is lower in diabetic adults 
than in children, probably due to more frequent 
infections and antibiotic therapies. Bismuth-based 
therapy has better results for H. pylori eradication 
in these patients, compared with the triple therapy 
(33). 
The treatment of recurrent respiratory 
infections or urogenital tract, often treated with 
antibiotics, is another cause of bacteria resistance to 
the drugs used in different regimens for H. pylori 
eradication. Amoxicillin, clarithromycin, metro-
nidazole and tetracycline are antibiotics used in 
first-line treatment of various respiratory or 
urogenital tract infections; in many cases, patients 
undergoing treatment for H. pylori eradication have 
used these antibiotics regimen for treating other 
infections.  
Increased resistance to levofloxacin in several 
European countries is also worrying because it 
opposes its use of empirical anti-H pylori treatment 
regimens without prior sensitivity tests (34). In the 
same study published by Megraud F, a significant 
positive association was shown between the use of 
antibiotics in the ambulatory and the primary 
degree of resistance observed in antimicrobial key 
agents used for the eradication of H pylori. 
Knowledge about the antibiotics used in a particular 
region or by every patient can provide information 
regarding the sensitivity or the resistance of H 
pylori not only to quinolones and macrolides, but 
also to other antibiotics, and thus the rehabilitation 
of the treatment strategies where the tests of 
sensitivity of H .pylori strains, isolated from the 
patient, are not available. 
H. pylori strains that grow in the presence of 
cholesterol are more resistant to multiple antibiotics 
(35). The antibiotics with this kind of resistance 
from the patients, in relation with cholesterol, are 
included in some treatment schemes used for to 
treat H. pylori infections, with recent work showing 
that H. pylori has a resistance dependent on bile 
salts cholesterol (36). This suggests that H. pylori 
can use the cholesterol modifying its envelope so as 
to resist to multiple antibiotics (37). 
Clarithromycin and tetracycline are antibiotics 
which inhibit protein synthesis and are used to treat 
H. pylori infection. A study based on  the effect of 
antibiotics on the viability of H. pylori cultivated in 
the presence or absence of cholesterol showed how 
cholesterol substantially increased H. pylori 
resistance to tetracyclin and clarithromycin.  
Ciprofloxacin and Metronidazole inhibit the 
DNA replication, and they are also used for the 
treatment of H. pylori infections. However, H. 
pylori grown with cholesterol was more resistant to 
ciprofloxacin than H. pylori grown without 
cholesterol. H. pylori grown with cholesterol 
showed a modest increase resistance to 
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metronidazole (about 10 to 30 times). For 
antibiotics that inhibit the biosynthesis of the cell 
wall, i.e., ampicillin and amoxicillin, there were 
similar results: H. pylori strains grown on the 
medium with cholesterol levels were up to 1,000 
times more resistant to antibiotics than those grown 
without cholesterol. Bismuth compounds are part of 
the regimen of H. pylori infection in some 
countries. H. pylori cultivated with cholesterol was 
significantly more resistant to bismuth (up to 107), 
than H. pylori bacteria grown without cholesterol. 
H. pylori grown without cholesterol was also more 
susceptible to rifampicin than H. pylori grown with 
cholesterol (35). 
2.Patient non-cooperation. Quitting the initial 
treatment. 
Many patients abandon treatment and the 
therapeutic scheme after being diagnosed with H. 
pylori infection, typically for two reasons: 
improvement and disappearance of symptoms of 
peptic ulcer; or the side effects of the treatment. The 
recurrence of symptoms at some time after giving 
up the initial treatment requires H. pylori culture, 
allowing thus antimicrobial susceptibility testing. 
The patient's support by the clinician about the 
awareness of the disease, information about the 
possible complications of this disease, and periodic 
evaluation during therapy is important for patient 
compliance to treatment and therapeutic success. 
Conclusions 
Helicobacter pylori infection is still a global 
concern, its diagnosis and  treatment may raise 
serious challenges. The diagnosis, the effective 
treatment and the revaluation of its effectiveness 
represents the prophylaxis of some diseases such as 
peptic ulcer, gastric lymphoma of mucosa-
associated lymphoid tissue (MALT) and gastric 
cancer. These diseases and their severe 
complications (bleeding, perforation) are life-
threatening for the patient. Treatment failure is due 
to the patient’s non-cooperation or his/her 
resistance to antibiotics; it varies depending on the 
patient’s country of origin, the patient him/herself, 
and previous prescriptions of antibiotics for other 
conditions. If the second treatment (as 
recommended by regional doctors) also fails, an 
endoscopy is required in order to have a biopsy 
sample from which to perform culture and DST. 
Although H. pylori treatment fails in about 20% of 
cases, moral support for the patient by the clinician, 
information about possible evolutional 
complications of H. pylori infection, and periodic 
evaluation of the patient during therapy, are 
important tools on which the therapeutic success 
depends. 
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